Candy Kumps
Ghent University Hospital
5 Papers
55 Citations
Candy Kumps is an academic researcher from Ghent University Hospital. The author has contributed to research in topics: Biology & Downregulation and upregulation. The author has an hindex of 4, co-authored 5 publications. Previous affiliations of Candy Kumps include Ghent University.
Chat about Author
Papers
The need for transparency and good practices in the qPCR literature
Stephen A. Bustin,Vladimir Benes,Jeremy A. Garson,Jan Hellemans,Jim F. Huggett,Mikael Kubista,Reinhold Mueller,Tania Nolan,Michael W. Pfaffl,Gregory L. Shipley,Carl T. Wittwer,Peter Schjerling,Philip J. R. Day,Mónica Abreu,Begoña Aguado,Jean-François Beaulieu,Anneleen Beckers,Sara Bogaert,John A. Browne,Fernando Carrasco-Ramiro,Liesbeth Ceelen,Kate L. Ciborowski,Pieter Cornillie,Stephanie Coulon,Ann Cuypers,Sara De Brouwer,Leentje De Ceuninck,Jurgen De Craene,Hélène De Naeyer,Ward De Spiegelaere,Kato Deckers,Annelies Dheedene,Kaat Durinck,Margarida Ferreira-Teixeira,Annelies Fieuw,Jack M. Gallup,Sandra Gonzalo-Flores,Karen Goossens,Femke Heindryckx,Elizabeth Herring,Hans Hoenicka,Laura Icardi,Rolf Jaggi,Farzad Javad,Michael Karampelias,Frederick S. B. Kibenge,Molly J. T. Kibenge,Candy Kumps,Irina Lambertz,Tim Lammens,Amelia Markey,Peter Messiaen,Evelien Mets,Sofia Morais,Alberto Mudarra-Rubio,Justine K. Nakiwala,Hilde Nelis,Pål A. Olsvik,Claudina Perez-Novo,Michelle Plusquin,Tony Remans,Ali Rihani,Paulo Rodrigues-Santos,Pieter Rondou,Rebecca Sanders,Katharina Schmidt-Bleek,Kerstin Skovgaard,Karen Smeets,Laura Tabera,Stefan Toegel,Tim Van Acker,Wim Van den Broeck,Joni Van der Meulen,Mireille Van Gele,Gert Van Peer,Mario Van Poucke,Nadine Van Roy,Sarah Vergult,Joris Wauman,Marina Tshuikina-Wiklander,Erik Willems,Sara Zaccara,Fjoralba Zeka,Jo Vandesompele +83 more
TL;DR: Two surveys of over 1,700 publications whose authors use quantitative real-time PCR (qPCR) reveal a lack of transparent and comprehensive reporting of essential technical information.
285
Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma : implications for targeted treatment
Irina Lambertz,Candy Kumps,Shana Claeys,Sven Lindner,Anneleen Beckers,Els Janssens,Daniel R. Carter,Alex Cazes,Belamy B. Cheung,Marilena De Mariano,David Camacho-Trujillo,An De Bondt,Sara De Brouwer,Jay Gibbons,I. Janoueix-Lerosey,Genevieve Laureys,Chris Liang,Glenn M. Marshall,Michaël Porcu,Junko Takita,Ilse Van den Wyngaert,Nadine Van Roy,Alan Van Goethem,Tom Van Maerken,Piotr Zabrocki,Jan Cools,Johannes H. Schulte,Jorge Vialard,Franki Speleman,Katleen De Preter +29 more
- 01 Jan 2015
TL;DR: The negative feedback loop of MAPK pathway inhibitors may affect novel ALK inhibition therapies, whereas mutant ALK induced RET signaling can offer novel opportunities for testing ALK-RET oriented molecular combination therapies.
43
ALK positively regulates MYCN activity through repression of HBP1 expression
Shana Claeys,Geertrui Denecker,Kaat Durinck,Bieke Decaesteker,Liselot Mus,Siebe Loontiens,Suzanne Vanhauwaert,Kristina Althoff,Caroline Wigerup,Daniel Bexell,Emmy Dolman,Kai Oliver Henrich,Lea Wehrmann,Ellen M. Westerhout,Jean-Baptiste Demoulin,Candy Kumps,Candy Kumps,Tom Van Maerken,Genevieve Laureys,Genevieve Laureys,Christophe Van Neste,Bram De Wilde,Bram De Wilde,Olivier De Wever,Frank Westermann,Rogier Versteeg,Jan J. Molenaar,Sven Påhlman,Johannes H. Schulte,Katleen De Preter,Frank Speleman +30 more
TL;DR: In this article, the PI3K-AKT-FOXO3a signaling axis was used to downregulate the HMG-box transcription factor 1 (HBP1) in high-risk primary neuroblastoma.
21
Effective Alu Repeat Based RT-Qpcr Normalization in Cancer Cell Perturbation Experiments
Ali Rihani,Tom Van Maerken,Filip Pattyn,Gert Van Peer,Anneleen Beckers,Sara De Brouwer,Candy Kumps,Evelien Mets,Joni Van der Meulen,Pieter Rondou,Carina Leonelli,Pieter Mestdagh,Franki Speleman,Jo Vandesompele +13 more
TL;DR: This study evaluated the expression levels of 11 commonly used reference genes as internal controls for normalization of 19 experiments that include neuroblastoma, T-ALL, melanoma, breast cancer, non small cell lung cancer, acute myeloid leukemia (AML), prostate cancer, colorectal cancer, and cervical cancer cell lines subjected to various perturbations.
17
ALK positively regulates MYCN activity through repression of HBP1 expression
Shana Claeys,Geertrui Denecker,Kaat Durinck,Bieke Decaesteker,Liselot Mus,Siebe Loontiens,Suzanne Vanhauwaert,Kristina Althoff,Caroline Wigerup,Daniel Bexell,Emmy Dolman,Kai Oliver Henrich,Lea Wehrmann,Ellen M. Westerhout,Jean-Baptiste Demoulin,Candy Kumps,Candy Kumps,Tom Van Maerken,Genevieve Laureys,Genevieve Laureys,Christophe Van Neste,Bram De Wilde,Bram De Wilde,Olivier De Wever,Frank Westermann,Rogier Versteeg,Jan J. Molenaar,Sven Påhlman,Johannes H. Schulte,Katleen De Preter,Frank Speleman +30 more
- 01 Jan 2019
TL;DR: It is shown that mutant ALK downregulates the ‘HMG-box transcription factor 1’ (HBP1) through the PI3K-AKT–FOXO3a signaling axis, suggesting a novel targeted therapy option for high-risk neuroblastoma.
15